Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses

Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2

(2015) Eric F. Zhu et al.   CANCER CELL

Macrophages and Therapeutic Resistance in Cancer

(2015) Brian Ruffell et al.   CANCER CELL

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

(2015) Padmanee Sharma et al.   CELL

Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution

(2015) Alice Tzeng et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tumor Angiogenesis in the Absence of Fibronectin or Its Cognate Integrin Receptors

(2015) Patrick A. Murphy et al.   PLoS One

Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy

(2014) Carola H. Ries et al.   CANCER CELL

Crucial Role of Aspartic Acid at Position 265 in the CH2 Domain for Murine IgG2a and IgG2b Fc-Associated Effector Functions

(2014) L. Baudino et al.   JOURNAL OF IMMUNOLOGY

Strategies To Inhibit Tumor Associated Integrin Receptors: Rationale for Dual and Multi-Antagonists

(2014) Helen M. Sheldrake et al.   JOURNAL OF MEDICINAL CHEMISTRY

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

(2014) Roger Stupp et al.   LANCET ONCOLOGY

Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment

(2013) Thomas F Gajewski et al.   CURRENT OPINION IN IMMUNOLOGY

Targeted inactivation of β1 integrin induces β3 integrin switching, which drives breast cancer metastasis by TGF-β

(2013) Jenny G. Parvani et al.   MOLECULAR BIOLOGY OF THE CELL

Engineered knottin peptide enables noninvasive optical imaging of intracranial medulloblastoma

(2013) Sarah J. Moore et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

 v Integrins in Angiogenesis and Cancer

(2013) S. M. Weis et al.   Cold Spring Harbor Perspectives in Medicine

Rational combinations of immunotherapeutics that target discrete pathways

(2013) Stefani Spranger et al.   Journal for ImmunoTherapy of Cancer

A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer

(2012) A. Heidenreich et al.   ANNALS OF ONCOLOGY

Raising the Bar: The Curative Potential of Human Cancer Immunotherapy

(2012) S. A. Rosenberg   Science Translational Medicine

Integrins as therapeutic targets

(2012) Simon L. Goodman et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma

(2011) S O'Day et al.   BRITISH JOURNAL OF CANCER

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

Tumor angiogenesis: molecular pathways and therapeutic targets

(2011) Sara M Weis et al.   NATURE MEDICINE

An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation

(2010) K. P. A. MacDonald et al.   BLOOD

A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin αvβ3, ± dacarbazine in patients with stage IV metastatic melanoma

(2010) Peter Hersey et al.   CANCER

PET Imaging of Tumor Neovascularization in a Transgenic Mouse Model with a Novel 64Cu-DOTA-Knottin Peptide

(2010) C. H. Nielsen et al.   CANCER RESEARCH

Dual Functional Monoclonal Antibody PF-04605412 Targets Integrin  5 1 and Elicits Potent Antibody-Dependent Cellular Cytotoxicity

(2010) G. Li et al.   CANCER RESEARCH

Endothelial  5 and  v integrins cooperate in remodeling of the vasculature during development

(2010) A. van der Flier et al.   DEVELOPMENT

Engineered Knottin Peptides: A New Class of Agents for Imaging Integrin Expression in Living Subjects

(2009) R. H. Kimura et al.   CANCER RESEARCH

Milk fat globule epidermal growth factor–8 blockade triggers tumor destruction through coordinated cell-autonomous and immune-mediated mechanisms

(2009) Masahisa Jinushi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors

(2009) Andrew R Reynolds et al.   NATURE MEDICINE

Engineered cystine knot peptides that bind αvβ3, αvβ5, and α5β1 integrins with low-nanomolar affinity

(2009) Richard H. Kimura et al.   PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS

Batf3 Deficiency Reveals a Critical Role for CD8 + Dendritic Cells in Cytotoxic T Cell Immunity

(2008) K. Hildner et al.   SCIENCE